Business Wire

TX-CIRRUS-LOGIC

25.6.2024 15:01:32 CEST | Business Wire | Press release

Share
Cirrus Logic Unveils Its Latest Additions to Its Family of Professional Audio Converters

Cirrus Logic (Nasdaq: CRUS) today unveiled the latest devices in its Pro Audio product family: a series of digital-to-analog converters (DACs) and an ultra-high performance audio CODEC that set a new standard for the prosumer and professional audio markets. These new solutions cater to the needs of recording artists, live performers, and audiophiles, delivering transparent audio converters to ensure recording and playback without any compromise in sound quality.

This launch expands on last year's successful analog-to-digital converters (ADCs) launch. Crafted with a focus on superior analog functionality and digital integration, these devices from Cirrus Logic offer exceptional performance, minimal power requirements, and innovative features like hybrid gain control, addressing longstanding audio challenges in the industry.

“True transparency in audio—that’s the hallmark of Cirrus Logic’s Pro Audio Family. It’s not just about sound, it’s about the authenticity from creation to consumption. Our commitment is purity in audio reproduction, ensuring that what you hear is as true to the original as possible,” said Eddie Sinnott, Director of Product Marketing. “With this new series of flagship audio products, we’re setting a gold standard for both professionals and prosumers, enabling our customers to create distinctive products with the confidence of our world-class engineering and support.”

Cirrus Logic CS4308P/CS4304P/CS4302P DACs and CS4282P CODEC

Designed with ease of use in mind, the Cirrus Logic Pro Audio 8-channel DAC CS4308P, 4-channel CS4304P, 2-channel CS4302P and CODEC CS4282P seamlessly integrate within a wide range of audio equipment. These new devices offer configurable advanced digital filters allowing our customers to define their signature sound. Cirrus Logic designs the devices with users in mind, making them as simple as possible to integrate and extract their full potential.

“As a long-time user of Cirrus Logic, we are excited about the new additions to its family of DAC and CODEC products being launched today,” said Simon Jones, CTO, Focusrite Group. “Cirrus Logic’s desire to keep setting the benchmark in audio quality is evident. These devices are designed to flawlessly integrate with a diverse spectrum of audio equipment, from USB audio interfaces to professional speakers and musical instruments. The addition of a hybrid gain control system into the CODEC and new ADC’s is a game changer for system integration that we really appreciate. At Focusrite, crafting audio interfaces is not just our business; it’s our passion. We bridge the gap between the artist and the audience, ensuring the sound conveyed is pristine.”

Exceptional Efficiency with Leading-Edge performance

The Pro Audio family also offers industry-leading power efficiency at 10 mW/ch for the 8/4-channel DACs, underlining Cirrus Logic’s longstanding commitment to bringing energy-efficient products to market. These new devices are 32-bit offering sample rates of up to 768 kHz, providing 129 dB of dynamic range for the CS4302P/CS4282P and 123 dB for the CS4304/8P. THD+N for these devices are all -114 dB or lower.

Product Availability

Samples of the CS4304/8P DACs and the CS4282P are available to order now. The converters are controllable and configurable using Cirrus Logic’s SoundClear® Studio software, which is available at www.cirrus.com. Samples of the CS4302P DAC will follow, later in the year.

Cirrus Logic Inc.

Cirrus Logic is a leader in low-power, high-precision mixed-signal processing solutions that create innovative user experiences for the world’s top mobile and consumer applications. With headquarters in Austin, Texas, Cirrus Logic is recognized globally for its award-winning corporate culture. Check us out at www.cirrus.com.

Cirrus Logic, Cirrus and the Cirrus Logic logo are registered trademarks of Cirrus Logic, Inc. All other company or product names noted herein may be trademarks of their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625199957/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release

One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye